louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03125850: Comparative Study of Psychology and Glaucoma Knowledge in Glaucoma Day-ward Patients Inpatients
Official title: Comparative Study of Psychology and Glaucoma Knowledge in Glaucoma Day-ward Patients Inpatients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Keywords: knowledge
psychology
Lead sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Sponsor class: OTHER
First posted: 2017-04-24
Enrollment: 240
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will compare the glaucoma day-ward patients' efficacy with inpatients by evaluating the glaucoma knowledge and psychology , and will analysis the reasons of the differences. Half of participants will receive treatment in day-ward, while the other half will receive treatment in hospital.

Detailed description: Ophthalmic surgery has short operative time, quick recovery, and small anesthesia risk, making day case surgery the main management mode of ophthalmic surgery. This study will explore the differences of psychology and glaucoma knowledge between glaucoma day-ward patients and the inpatients. The data will be collected by scale on admission and discharge.

Eligibility criteria: Inclusion Criteria:

1. Patient is diagnosed with glaucoma;
2. Will receive glaucoma surgery;
3. Voluntary participation in this study;
4. Have enough language comprehension ability;
5. Best corrected visual acuity reach 0.1 or better;
6. Patient or his legal representative has sign the informed consent.

Exclusion Criteria:

1. Patient with mental disorder;
2. There are important viscera function failure or other serious disease, including clinical related coronary artery disease, cardiovascular disease or myocardial infarction into the group of the first six months; serious neurological or psychiatric illness; serious infections; coagulant function abnormality; general active infectious diseases; malignant tumor; serious immune diseases;
3. Patient with monocular blindness;
4. Axial length≤20 mm;
5. With other serious eye diseases;
6. Neurologic diseases that could affect the visual field;
7. 3 months prior to research to participate in any clinical study;
8. Researchers think not suitable to participate in this clinical trial subjects;
9. Refused to sign the informed consent.

Primary outcomes:
measure: Change of depression and anxiety score
timeFrame: at baseline and 1 hour before discharge
measure: Change of glaucoma knowledge score
timeFrame: at baseline and 1 hour before discharge
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center, Sun Yat-San Univerdity
state: Guangdong
Study officials:
affiliation: Zhongshan Ophthalmic Center, Sun Yat-San University
name: Mingkai Lin, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03877250: Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies
Official title: Characterization of Mechanism of Response to PD-1 Blockade in NSCLC: A Pilot Study
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Non Small Cell Lung Cancer
Keywords: PD-L1 High
19-030
Memorial Sloan Kettering Cancer Center
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: Wang Initiative in Lung Cancer Clinical Trials
First posted: 2019-03-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants with newly diagnosed or recurrent, PD-L1 high (\>50%) metastatic non-small cell lung cancer without prior PD-(L)1 therapy

Brief summary: The purpose of this study is to attempt to obtain an on-treatment biopsy in participants with non-small cell lung cancer who are receiving standard treatment with a drug that targets the PD-1 or PD-L1 protein.


Eligibility criteria: Inclusion Criteria:

* Pathologically confirmed newly diagnosed or recurrent advanced Non Small Cell Lung Cancer/NSCLC that is PI-L1 high by immunohistochemistry (PD-L1 \>/= 50%)
* Intended treatment with a PD-(L)1 inhibitor
* Age \>/= 18 years
* Karnofsky Performance Status \>/= 70% and medically fit to undergo a biopsy procedure

Exclusion Criteria:

* Any medical condition or any sites of disease that would preclude a biopsy
* Pregnant or breastfeeding women
* Cognitively impairment affecting ability to understand and provide informed consent
* Prior PD-(L)1 blockade treatment
* Chemotherapy within 6 months prior to enrollment

Primary outcomes:
measure: Number of participants biopsied on-treatment and with newly diagnosed or recurrent PD-L1 advanced Non Small Cell Lung Cancer/NSCLC
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Memoral Sloan Kettering Basking Ridge (Consent and Follow up)
state: New Jersey
city: Middletown
country: United States
facility: Memoral Sloan Kettering Monmouth (Consent and Follow up)
state: New Jersey
city: Montvale
country: United States
facility: Memorial Sloan Kettering Bergen (Consent and Follow up)
state: New Jersey
city: Commack
country: United States
facility: Memorial Sloan Kettering Cancer Center @ Suffolk (Consent Only)
state: New York
city: Harrison
country: United States
facility: Memoral Sloan Kettering Westchester (Consent & Follow Up)
state: New York
city: New York
country: United States
facility: Memorial Sloan - Kettering Cancer Center (Consent and follow-up)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Matthew Hellmann, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05820750: Clinical and Radiographic Evaluation of Photodynamic Therapy for Root Canal Treatment of Primary Molars
Official title: Clinical and Radiographic Evaluation of Photodynamic Therapy for Root Canal Treatment of Primary Molars
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Photodynamic Therapy
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2023-04-20
Enrollment: 60
Sex: ALL
Minimum age (years): 4
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be conducted to evaluate clinical and radiographic success of Photodynamic Therapy for root canal treatment of primary molars in comparison to the standard root canal treatment.


Eligibility criteria: Inclusion Criteria:

* Children aged 4-7 years.
* Apparent healthy child not suffering from any mental or physical disability.
* Cooperative children.
* Restorable teeth.
* Each child should have at least one carious primary molar with signs and symptoms of irreversible pulpitis or pulp necrosis.
* Absence of internal and / or external perforation in the furcation area.
* At least 2/3 thirds of the roots should be remained.

Exclusion Criteria:

* Children with compromised health or physical disability.
* Resorption of the roots more than 2/3 thirds.
* Non restorable teeth.

Primary outcomes:
measure: Evaluation of clinical success of photodynamic therapy
timeFrame: 14 months
measure: Evaluation of radiographic success of photodynamic therapy
timeFrame: 14 months
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mohamed El Sayed Abo Farrag
Study officials:
References:
Clinical trial NCT02994550: Influence of FSH/LH Ratio in Controlled Ovarian Stimulation
Official title: Influence of FSH/LH Ratio in Controlled Ovarian Stimulation ( 2/1 Ratio vs 4/1 Ratio) in >35 Years Women Undergoing IVF
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Sub-Fertility
Keywords: FSH
LH
IVF
Lead sponsor: Hospital de Cruces
Sponsor class: OTHER
First posted: 2016-12-16
Enrollment: 447
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare different FSH/LH ratios in controlled ovarian stimulation


Eligibility criteria: Inclusion Criteria:

* Patients undergoing IVF cycles in Cruces University Hospital.
* Signed IVF and cryopreservation informed consent.
* Age \>35 and \<40 years.
* FSH levels \<10 mIU/ml.

Exclusion Criteria:

* When inclusion criteria are not fulfilled

Primary outcomes:
measure: Pregnancy achievement
timeFrame: 3 months after drug administration
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01936350: Sildenafil Impact on Ventricular Function in Patients With Heart Failure
Official title: Sildenafil Impact on Ventricular Function in Patients With Heart Failure: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Heart Failure
Keywords: Heart failure
Lead sponsor: Hospital Ana Nery
Sponsor class: OTHER
First posted: 2013-09-06
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Twenty-four patients with known heart failure will be recruited. They will undergo a cardiac magnetic resonance for ventricular analyses and after this first exam they will be randomized to placebo or Sildenafil. After one hour drug intake they will undergo another cardiac magnetic resonance to evaluate the drug impact on right and left ventricular function.

Detailed description: Twenty-four patients with known heart failure will be recruited. They will undergo a cardiac magnetic resonance for ventricular analyses and after this first exam they will be randomized to placebo or sildenafil. After one hour drug intake they will undergo another cardiac magnetic resonance to evaluate the drug impact on right and left ventricular function.

The first and second exams will be performed by the same staff. All patients will be evaluated by two, three and four chambers view. Left and right ventricle quantification analyses will be performed by Argus software.

Eligibility criteria: Inclusion Criteria: Patients with heart failure in stable clinical condition compatible with New York Heart Association functional class I to III. Eligibility criteria is consent to participate in the study after receiving detailed information about procedures, possible clinical benefits, and risks.

Exclusion Criteria: patients with new diagnosed lesions during the procedure, eg pulmonary mass and important claustrophobia, low blood pressure ( systolic blood pressure \<90 mmHg or diastolic blood pressure \<60 mmHg) nitrate or nebivolol use over the last 48 hours, metallic non MRI compatible implantable devices.

Primary outcomes:
measure: Improvement on ventricular function
timeFrame: one hour
Secondary outcomes:
Other outcomes:
Locations:
city: Salvador
country: Brazil
facility: Hospital Ana Neri - MRI unit
state: Bahia
Study officials:
affiliation: Hospital Ana Nery - Federal University of Bahia
name: Andre M Fernandes, Master
role: STUDY_DIRECTOR
References:
citation: Fernandes AM, Andrade AC, Barroso ND, Borges IC, Carvalho-Andrade D, Rodrigues Junior ES, Guimaraes LC, Duraes AR, Borges SM, Aras Junior R. The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial. PLoS One. 2015 Mar 20;10(3):e0119623. doi: 10.1371/journal.pone.0119623. eCollection 2015.
Clinical trial NCT05594550: Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection
Official title: Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Respiratory Distress Syndrom (SARS-Cov 2)
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2022-10-26
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults with acute respiratory syndrome due to SARS-Cov-2

Brief summary: Sarcopenia is a risk factor for adverse outcome in critically ill patients. Sarcopenia might be estimated from muscle surface measure on tomodensitometry.

The purpose of the study is to identify if muscle surfaces measured on thoracic tomodensitometry are associated with mortality in patients with acute respiratory distress syndrome due to SARS-Cov-2.


Eligibility criteria: Inclusion Criteria:

* patients hospitalized in intensive care for SARS-Cov-2 infection since january 2020
* Thoracic TDM within the 30 day preceding ICU admission and up to 24 hours after ICU admission

Exclusion Criteria:

* Pregnancy
* Neuromuscular disease

Primary outcomes:
measure: measurement of muscle area at T7 level indexed in cm²/m².
timeFrame: At hospital admission
Secondary outcomes:
measure: Duration of mechanical ventilation
timeFrame: within the 28 days
measure: Ventilator free days
timeFrame: within the 28 days
measure: number of days in Intensive care unit
timeFrame: within the 28 days
measure: number of days in hospital
timeFrame: within the 28 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01291550: Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Neurodegenerative Diseases
Keywords: Detecting volatile biomarkers using breath sample
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
Collaborators: name: Technion, Israel Institute of Technology
First posted: 2011-02-08
Enrollment: 300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Out patient clinic patients diagnosed with neurodegenerative conditions healthy control and subjects diagnosed with ADHD.

Brief summary: The diagnosis of neurodegenerative conditions and ADHD still mostly relies on clinical symptoms as there are no validated, inexpensive, and simple bio- markers available yet. The purpose of this study is to deliver a proof-of-concept for novel biomarkers to identify neurodegenerative conditions and ADHD based on breath testing.

Alveolar breath will be collected from healthy volunteers, patients with extrapyramidal conditions, patients diagnosed with dementia and from ADHD subjects. The discriminative power of a tailor-made Nanoscale Artificial Nose (™NA-NOSE) containing an array of six nanomaterial-based sensors will be tested. Discriminant factor analysis will be applied to the NA-NOSE signals in order to detect statistically significant differences between the sub-populations, and classification success will be estimated using leave-one-out cross-validation. The identification of NA-NOSE patterns will be supported by analyzing the chemical composition of the breath using gas-chromatography in conjunction with mass-spectrometry (GC-MS).


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with neurodegenerative conditions
* Healthy subjects
* Subjects diagnosed with ADHD

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Cognitive Neurology, Rambam Medical Center
Study officials:
References:
citation: Tisch U, Schlesinger I, Ionescu R, Nassar M, Axelrod N, Robertman D, Tessler Y, Azar F, Marmur A, Aharon-Peretz J, Haick H. Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors. Nanomedicine (Lond). 2013 Jan;8(1):43-56. doi: 10.2217/nnm.12.105. Epub 2012 Oct 15.
Clinical trial NCT00588250: Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates
Official title: Prospective Randomized Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Embryo Implantation
Infertility
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2008-01-08
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Hypothesis: a special solution for improving human embryo implantation, when added to the solution during embryo transfer, will improve implantation rates in embryo transfers using previously frozen embryos.

Detailed description: EmbryoGlue (TM) is added to embryo transfer solutions immediately prior to the transfer of frozen-thawed human embryos before placement of embryos into the patient uterus.

Eligibility criteria: Inclusion Criteria:

* Frozen embryo transfer patients, men over the age of 18 and women between the ages of 18 and 42 completed years (if using their own eggs and with embryos frozen before 39 completed years) or 18 to 50 completed years if using donated eggs.

Exclusion Criteria:

* Prior participation in this study, blastocyst transfers, single embryo transfer for medical reasons, prior embryo transfer with large amount of blood on the outside of the catheter, \> or = 3 consecutive failed embryo transfers at Mayo Clinic (fresh or frozen-thawed cycles).

Primary outcomes:
measure: Pregnancy Rate
timeFrame: one month
Secondary outcomes:
measure: Implantation rate
timeFrame: two months
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Dean E Morbeck, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00776750: Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
Official title: Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hemodialysis
Renal Transplantation
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2008-10-21
Enrollment: 407
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Disturbances of acquired immunity are considered to be responsible, at least partly, for the high infection rate and inadequate response to vaccinations observed in hemodialysis (HD) patients and renal transplant recipient (RTR). The present prospective trial aims at (a) evaluating the immunogenicity of a standard influenza vaccine in HD and RTR patients and (b) at identifying determinants of the immune response.


Eligibility criteria: Inclusion Criteria:

* maintenance hemodialysis patients or
* renal transplant recipients (beyond month 3 after transplantation)

Exclusion Criteria:

* patients with known allergy to chicken proteins

Primary outcomes:
measure: Seroprotection rate, defined as the percentage of patients with an HI antibody titer ≥ 40,
Secondary outcomes:
measure: Seroresponse rate, defined as the percentage of patients with a fourfold rise in HI titer after vaccination; impact of booster vaccination on the immune response, and safety of influenza vaccination.
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Hospital Leuven
Study officials:
affiliation: Universitaire Ziekenhuizen KU Leuven
name: Yves Vanrenterghem, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Scharpe J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, Osterhaus AD, Vanrenterghem Y, Evenepoel P. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis. 2009 Jul;54(1):77-85. doi: 10.1053/j.ajkd.2008.11.032. Epub 2009 Apr 1.
Clinical trial NCT04180150: A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
Official title: A Randomized, Double-blinded, Placebo-controlled, Phase IIa Study of TQ-A3334 Combined With Entecavir in the Treatment of Untreated or HBV DNA Negative Subjects With Chronic Hepatitis B
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Chronic Hepatitis B
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2019-11-27
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative subjects with Chronic Hepatitis B.


Eligibility criteria: Inclusion Criteria:

* 1. 18 and 65 years old ; 2. HBsAg positive at least for 6 months ; 3. HBeAg positive chronic hepatitis B, HBV DNA \> 10\^5 copies/ml; 4. Fibroscan ≤ 12.4 Kpa，2×ULN ≤ ALT ≤ ULN; 5. New diagnosed chronic hepatitis B subjects;

Exclusion Criteria:

* 1.Combined with other virus infection ; 2.Has cirrhosis or hepatocellular carcinoma; 3.Has autoimmune diseases; 4.Has thyroid disease; 5.Has eye diseases; 6.Has clinically significant abnormalities/diseases ≥ grade 2; 7.Has history of chronic kidney disease, renal insufficiency, renal anemia; 8.Peripheral blood index is low; 9.Has a history of allergy to experimental drugs or their excipients; 10.Has participated in other clinical trials within 3 months; 11.Breastfeeding or pregnant women.; Men unwilling to use adequate contraceptive measures during the study; 12.According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.; 13.Has history of drug abuse in the past five years;

Primary outcomes:
measure: Cmax
timeFrame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.
measure: Tmax
timeFrame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.
measure: AUC0-t
timeFrame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.
measure: Cytokine
timeFrame: Hour 0, 1.5 , 12 , 24 , 72 hours post-dose at week 1 and week 12; Hour 0 at week 7.
Secondary outcomes:
measure: HBV biomarker
timeFrame: Day 1 pre-dose, day 84, day 168, day 336 post-dose.
measure: Lymphocyte function
timeFrame: Hour 0 pre-dose, day 56, day 84, day 168 at post-dose.
Other outcomes:
Locations:
city: Chongqing
country: China
facility: The second affiliated hospital of chongqing medical university
state: Chongqing
city: Changchun
country: China
facility: The first hospital of Jilin University
state: Jinlin
Study officials:
References: